Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18851087 | Hybridoma cell line secreting an ActA monoclonal antibody and use thereof | September 2024 | July 2025 | Allow | 10 | 1 | 1 | No | No |
| 18814445 | MULTI-ANTIGEN DIAGNOSTIC FOR DETECTING LYME DISEASE | August 2024 | January 2026 | Allow | 17 | 3 | 1 | Yes | No |
| 18737799 | COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS | June 2024 | April 2025 | Abandon | 10 | 2 | 0 | Yes | No |
| 18633805 | DIETARY SUPPLEMENT COMPOSITION FOR TREATING AND MANAGING ACNE | April 2024 | September 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18632343 | OSTRICH ANTIBODY FOR BACTERIAL INFECTIOUS DISEASES | April 2024 | October 2025 | Allow | 19 | 2 | 0 | No | No |
| 18600406 | PRODUCTION OF INDOLE-DERIVED METABOLITES BY SHELF-STABLE COMMUNITIES OF SAFE BACTERIA | March 2024 | October 2025 | Abandon | 19 | 3 | 0 | Yes | No |
| 18438693 | ANTI-PNEUMOCOCCAL HYPERIMMUNE GLOBULIN FOR THE TREATMENT AND PREVENTION OF PNEUMOCOCCAL INFECTION | February 2024 | December 2025 | Allow | 22 | 1 | 0 | No | No |
| 18430254 | ETHYL 2-[9-(2-HYDROXYPYRIDIN-3-YL)-3,6-DIPHENYL-1,8-DIOXO-3,4,9,10-TETRAHYDROACRIDINE-10-YL]-ACETATE AS AN ANTIMICROBIAL COMPOUND | February 2024 | March 2025 | Allow | 14 | 2 | 0 | No | No |
| 18518117 | METHODS AND ARRAYS FOR TARGET ANALYTE DETECTION AND DETERMINATION OF TARGET ANALYTE CONCENTRATION IN SOLUTION | November 2023 | May 2025 | Abandon | 18 | 2 | 0 | No | No |
| 18506072 | COMPOSITIONS AND METHODS FOR DETECTING PROTEASE ACTIVITY IN BIOLOGICAL SYSTEMS | November 2023 | April 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18386555 | ETHYL 2-[9-(2-HYDROXYPYRIDIN-3-YL)-3,6-DIPHENYL-1,8-DIOXO-3,4,9,10- TETRAHYDROACRIDINE-10-YL]-ACETATE AS AN ANTIMICROBIAL COMPOUND | November 2023 | February 2024 | Allow | 3 | 0 | 1 | No | No |
| 18469188 | PHARMACEUTICAL COMPOSITION COMPRISING A PROBIOTIC AND PREBIOTIC TO PREVENT ACQUISITION OF OR TREAT DRUG RESISTANT INFECTIONS | September 2023 | April 2025 | Abandon | 18 | 2 | 1 | Yes | Yes |
| 18262969 | USE OF PHARMACEUTICAL COMPOSITION CONTAINING CHLOROGENIC ACID IN PREPARATION OF MEDICAMENT FOR TREATING PATHOLOGIC JAUNDICE | July 2023 | March 2026 | Abandon | 32 | 1 | 0 | No | No |
| 18356890 | NOVEL STREPTOCOCCUS SALIVARIUS STRAIN HAVING ANTIBACTERIAL, ANTIFUNGAL, ANTI-INFLAMMATORY ACTIVITY AND INHIBITING DENTAL CARIES AND ORAL COMPOSITION COMPRISING THE SAME | July 2023 | September 2025 | Abandon | 26 | 1 | 1 | Yes | No |
| 18217206 | FAST DIAGNOSIS AND PERSONALIZED TREATMENTS FOR ACNE | June 2023 | May 2025 | Abandon | 23 | 1 | 1 | No | No |
| 18265426 | MICROORGANISM WITH HIGH TRIPEPTIDE PRODUCTIVITY AND USE THEREOF | June 2023 | March 2026 | Allow | 33 | 1 | 0 | No | No |
| 18139626 | Anti-PfRH5 Antibodies and Antigen-Binding Fragments Thereof | April 2023 | May 2024 | Allow | 13 | 0 | 0 | No | No |
| 18033221 | LATERAL FLOW ASSAY FOR RAPID DETECTION OF PATHOGENS IN SAMPLES | April 2023 | January 2026 | Abandon | 33 | 0 | 1 | No | No |
| 18129936 | ANTIBODY DETECTION TEST STRIP OF INTEGRATING PRIMARY SCREENING AND DIAGNOSIS OF BOVINE BRUCELLOSIS | April 2023 | December 2025 | Allow | 33 | 1 | 0 | No | No |
| 18295211 | True human antibody specific for interleukin 1 alpha | April 2023 | November 2025 | Allow | 31 | 0 | 0 | No | No |
| 18130005 | ANTIBODY DETECTION TEST STRIP OF INTEGRATING PRIMARY SCREENING AND DIAGNOSIS OF SHEEP BRUCELLOSIS | April 2023 | January 2026 | Allow | 34 | 1 | 0 | No | No |
| 18194406 | DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE IN A FELINE | March 2023 | March 2026 | Abandon | 36 | 1 | 1 | No | No |
| 18192505 | USE OF KLK5 ANTAGONISTS FOR THE TREATMENT OF A DISEASE | March 2023 | November 2024 | Abandon | 20 | 0 | 1 | No | No |
| 18182055 | COMPOSITIONS AND METHODS FOR THE INDUCTION OF CD8+ T-CELLS | March 2023 | October 2024 | Allow | 20 | 3 | 0 | Yes | No |
| 18179190 | METHODS AND COMPOSITIONS RELATING TO ASSESSMENT FOR INFERTILITY | March 2023 | January 2026 | Abandon | 34 | 1 | 0 | No | No |
| 18018178 | MICROBIOME MEDIATED INDUCTION OF IMMUNE TOLERANCE AND RESOLUTION OF INFLAMMATION | January 2023 | December 2025 | Abandon | 35 | 1 | 0 | No | No |
| 18097887 | IMMUNOLOGICAL DETECTION METHOD AND KIT FOR MYCOPLASMA PNEUMONIAE | January 2023 | October 2025 | Abandon | 33 | 3 | 1 | Yes | No |
| 18149612 | PEPTIDES AND METHODS FOR THE DETECTION OF LYME DISEASE ANTIBODIES | January 2023 | July 2024 | Abandon | 18 | 1 | 0 | No | No |
| 18068725 | HUMAN-DERIVED BACTERIA THAT INDUCE PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS | December 2022 | July 2025 | Allow | 31 | 2 | 1 | No | No |
| 18074884 | MULTIVALENT PNEUMOCOCCAL VACCINE COMPOSITIONS COMPRISING POLYSACCHARIDE-PROTEIN CONJUGATES | December 2022 | February 2026 | Abandon | 39 | 1 | 1 | No | No |
| 17997635 | RAPID LATERAL FLOW ASSAY FOR VIBRIO DETECTION | October 2022 | March 2026 | Abandon | 41 | 1 | 1 | No | No |
| 18049993 | METHODS AND COMPOSITIONS FOR DETECTING FUNGI AND MYCOTOXINS | October 2022 | November 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17952761 | ASSAYS FOR DETERMINING THE PATHOGENCITY OF TOXOPLASMA INFECTIONS | September 2022 | February 2024 | Abandon | 16 | 1 | 0 | No | No |
| 17934054 | ALPHA-HEMOLYSIN VARIANTS WITH ALTERED CHARACTERISTICS | September 2022 | March 2024 | Allow | 18 | 1 | 1 | Yes | No |
| 17860961 | BLOCKING ELISA KIT FOR DETECTING ANTIBODY TO SWINE ACUTE DIARRHEA SYNDROME CORONAVIRUS N PROTEIN | July 2022 | February 2026 | Abandon | 43 | 1 | 1 | No | No |
| 17782163 | SYSTEM AND METHODS FOR MANIPULATION OF THE ORAL MICROBIOME IN MAMMALS | June 2022 | January 2026 | Abandon | 44 | 2 | 0 | Yes | No |
| 17739553 | ANTI-MICROBIAL SEAWEED EXTRACTS, COMPOSITIONS AND USES THEREOF | May 2022 | January 2024 | Abandon | 21 | 1 | 0 | No | No |
| 17662188 | PROBIOTIC COMPOSITIONS FOR PRODUCTION OF DOPAMINE | May 2022 | June 2025 | Allow | 37 | 4 | 0 | Yes | No |
| 17767994 | STRAINS AND PROCESSES FOR SINGLE CELL PROTEIN OR BIOMASS PRODUCTION | April 2022 | December 2025 | Allow | 44 | 2 | 1 | Yes | No |
| 17766104 | HIGH THROUGHPUT, FLUORESCENCE-BASED ESTIMATION OF MONOCLONAL ANTIBODY AGGREGATION WITH DISODIUM 3,3'-{[(E)-1,2-DIPHENYL-1,2-ETHENEDIYL]BIS(4,1-PHENYLENEOXY)}DI (1-PROPANESULFONATE) DYE FOR SUPERIOR SENSITIVITY AND SPECIFICITY | April 2022 | November 2025 | Allow | 44 | 2 | 1 | Yes | No |
| 17711081 | PROBIOTICS FOR USE IN THE PREVENTION OR TREATMENT OF ILLNESS AND/OR SYMPTOMS ASSOCIATED WITH CORONAVIRUSES | April 2022 | September 2023 | Allow | 17 | 1 | 0 | No | No |
| 17705619 | MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES | March 2022 | February 2024 | Allow | 23 | 1 | 0 | No | No |
| 17702854 | COMPOSITIONS COMPRISING BACTERIAL STRAINS | March 2022 | March 2024 | Abandon | 24 | 1 | 0 | No | No |
| 17699302 | O-Mannosyltransferase Deficient Filamentous Fungal Cells and Methods of Use Thereof | March 2022 | September 2025 | Abandon | 41 | 3 | 1 | No | No |
| 17674932 | MENINGOCOCCAL B RECOMBINANT VACCINE | February 2022 | March 2024 | Allow | 25 | 3 | 1 | Yes | No |
| 17633330 | COMPOSITION FOR INHIBITING REDUCTION OF TESTOSTERONE AND/OR DIHYDROTESTOSTERONE | February 2022 | March 2026 | Abandon | 49 | 2 | 0 | No | Yes |
| 17591631 | DIAGNOSTIC METHOD EMPLOYING HNL | February 2022 | January 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17584956 | BACTERIA ENGINEERED TO TREAT METABOLIC DISEASES | January 2022 | September 2023 | Allow | 19 | 1 | 0 | Yes | No |
| 17555761 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INDUCING IMMUNE TOLERANCE BY MUCOSAL VACCINATION WITH FC-COUPLED ANTIGENS | December 2021 | December 2025 | Abandon | 48 | 5 | 0 | No | No |
| 17595998 | TETRASACCHARIDES FOR THE DIAGNOSIS, PREVENTION, AND TREATMENT OF MELIOIDOSIS AND GLANDERS | December 2021 | March 2025 | Allow | 39 | 1 | 1 | No | No |
| 17534970 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROPHYLAXIS AND TREATMENT OF LYME DISEASE | November 2021 | March 2025 | Allow | 40 | 5 | 1 | No | No |
| 17453529 | PORTABLE DEVICE AND SYSTEM FOR RAPID DETECTION OF A BACTERIAL CELL IN FLUID SAMPLES | November 2021 | September 2025 | Allow | 46 | 1 | 1 | No | No |
| 17608242 | VAGINAL MICROBIOME MARKERS FOR PREDICTION OF PREVENTION OF PRETERM BIRTH AND OTHER ADVERSE PREGNANCY OUTCOMES | November 2021 | April 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17508692 | TREATMENT OF STAPHYLOCOCCAL DISORDERS | October 2021 | April 2024 | Allow | 29 | 1 | 1 | No | No |
| 17498278 | METHODS FOR TREATING NEPHROTIC SYNDROME | October 2021 | August 2023 | Allow | 22 | 1 | 0 | No | No |
| 17496926 | METHODS AND ARRAYS FOR TARGET ANALYTE DETECTION AND DETERMINATION OF TARGET ANALYTE CONCENTRATION IN SOLUTION | October 2021 | July 2023 | Allow | 21 | 2 | 1 | Yes | No |
| 17600743 | METHOD FOR DETECTING OR MONITORING THE PROGRESSION OF A CHRONIC AUTOIMMUNE DISEASE BY IMMUNOASSAY | October 2021 | May 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17481606 | FLUID HANDLING DEVICE | September 2021 | October 2024 | Abandon | 37 | 0 | 1 | No | No |
| 17460658 | NOVEL PNEUMOCOCCAL VACCINE FORMULATIONS | August 2021 | December 2023 | Abandon | 28 | 2 | 1 | Yes | No |
| 17410908 | BACTERIAL VACCINE COMPONENTS AND USES THEREOF | August 2021 | December 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17403284 | DIRECT-FED MICROBIALS | August 2021 | July 2023 | Allow | 23 | 1 | 0 | No | No |
| 17400441 | ENGINEERED BOTULINUM NEUROTOXIN | August 2021 | November 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17397915 | ANTI-PNEUMOCOCCAL HYPERIMMUNE GLOBULIN FOR THE TREATMENT AND PREVENTION OF PNEUMOCOCCAL INFECTION | August 2021 | October 2023 | Allow | 26 | 1 | 1 | No | No |
| 17419855 | BACTERIAL VACCINE | June 2021 | April 2025 | Allow | 46 | 3 | 0 | Yes | No |
| 17358086 | BACTERIAL VACCINE COMPONENTS AND USES THEREOF | June 2021 | November 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17417364 | NUCLEIC ACID DETECTION | June 2021 | October 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17354161 | METHOD FOR PREVENTING OR TREATING NOSOCOMIAL PNEUMONIA | June 2021 | September 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17350690 | Methods And Compositions For Improved Production Of Fatty Acids And Derivatives Thereof | June 2021 | October 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17351032 | Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureus | June 2021 | February 2026 | Abandon | 56 | 4 | 1 | No | No |
| 17349627 | ACTIVE SUBSTANCE OF MORCHELLA, ITS USE AND A COMPOSITION THEREOF FOR IMPROVING THE REPRODUCTIVE FUNCTION | June 2021 | May 2023 | Allow | 23 | 2 | 0 | No | No |
| 17340532 | Compositions and Methods Related to Protein A (SpA) Variants | June 2021 | November 2023 | Allow | 29 | 1 | 0 | No | No |
| 17297385 | BIOSENSOR AND METHOD FOR DETECTION OF ANALYTES | May 2021 | June 2025 | Allow | 49 | 1 | 1 | No | No |
| 17246167 | COMPOSITIONS AND METHODS FOR DETECTING PROTEASE ACTIVITY IN BIOLOGICAL SYSTEMS | April 2021 | August 2023 | Allow | 27 | 1 | 0 | No | No |
| 17290385 | HAFNIA ALVEI FORMULATIONS | April 2021 | September 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17288909 | COMPOSITIONS AND METHODS FOR OCHROBACTRUM-MEDIATED PLANT TRANSFORMATION | April 2021 | August 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17240433 | PROBIOTICS FOR USE IN THE PREVENTION OR TREATMENT OF ILLNESS AND/OR SYMPTOMS ASSOCIATED WITH CORONAVIRUSES | April 2021 | December 2021 | Allow | 8 | 2 | 1 | Yes | No |
| 17288308 | KITS AND METHODS FOR REAL-TIME MULITPLEX DETECTION AND IDENTIFICATION OF PATHOGENS | April 2021 | November 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17231526 | MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES | April 2021 | December 2021 | Allow | 8 | 1 | 1 | No | No |
| 17228382 | DIAGNOSIS AND TREATMENT OF INVASIVE ASPERGILLOSIS | April 2021 | February 2023 | Allow | 22 | 1 | 0 | No | No |
| 17277857 | Multiple Heteroresistance to Guide Combination Antibiotic Regimens | March 2021 | August 2025 | Allow | 53 | 2 | 1 | Yes | No |
| 17277592 | COMPOSITION AGAINST RESISTANT ORGANISMS (MRSA) | March 2021 | November 2023 | Abandon | 32 | 1 | 0 | No | No |
| 17200553 | COMPOSITIONS AND METHODS FOR DIAGNOSING LYME DISEASE AND FOR PREDICTING LYME DISEASE SPIROCHETE ELIMINATION AFTER TREATMENT | March 2021 | April 2024 | Allow | 37 | 1 | 1 | Yes | No |
| 17186366 | Vaccine Adjuvant | February 2021 | May 2024 | Allow | 39 | 2 | 1 | No | No |
| 17178412 | COMPOSITIONS AND METHODS FOR TREATING AN INFLAMMATORY DISEASE OR DISORDER | February 2021 | July 2023 | Abandon | 29 | 1 | 1 | No | No |
| 17268500 | RAPID DIAGNOSTICS OF MYCOBACTERIA WITH LECTIN CONJUGATED PARTICLES | February 2021 | November 2022 | Abandon | 21 | 2 | 0 | No | No |
| 17268380 | METHOD AND COMPOSITION FOR STIMULATING IMMUNE RESPONSE | February 2021 | May 2024 | Abandon | 39 | 1 | 1 | No | No |
| 17149227 | PEPTIDES AND METHODS FOR THE DETECTION OF LYME DISEASE ANTIBODIES | January 2021 | October 2022 | Allow | 21 | 0 | 0 | No | No |
| 17259457 | PREVENTING FUNGAL GROWTH IN HONEY BEE COLONIES AND RELATED MATERIALS AND METHODS | January 2021 | March 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17142792 | VIRB10 FOR VACCINATION AGAINST GRAM NEGATIVE BACTERIA | January 2021 | August 2024 | Allow | 43 | 3 | 0 | Yes | No |
| 17133589 | APPARATUS AND METHOD FOR PROCESSING SAMPLES CONTAINING BIOLOGICAL CELLS | December 2020 | September 2025 | Allow | 57 | 3 | 0 | No | No |
| 17115827 | IMMUNIZATION WITH POLYVALENT VENOM VACCINES | December 2020 | July 2022 | Allow | 19 | 2 | 0 | No | No |
| 17116353 | METHODS FOR CONTROLLING PROTEASE PRODUCTION | December 2020 | February 2024 | Allow | 38 | 4 | 0 | Yes | No |
| 17059918 | BIOMARKERS FOR THE DIAGNOSIS OF INVASIVE FUNGAL INFECTIONS | November 2020 | August 2024 | Allow | 45 | 2 | 0 | Yes | No |
| 17093133 | MODIFIED BACTERIA HAVING IMPROVED PHARMACOKINETICS AND TUMOR COLONIZATION ENHANCING ANTITUMOR ACTIVITY | November 2020 | June 2023 | Allow | 32 | 1 | 1 | Yes | No |
| 17053232 | Methods and Compositions for Treating or Preventing Gut Barrier Dysfunction | November 2020 | January 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17051653 | PROBIOTIC BIFIDOBACTERIUM BREVE STRAIN AND COMPOSITIONS COMPRISING SAID STRAIN | October 2020 | January 2023 | Allow | 26 | 1 | 0 | Yes | No |
| 17050666 | Non-integrative Listeria-based vaccine and method for inducing antitumor immune response | October 2020 | February 2023 | Allow | 28 | 1 | 1 | No | No |
| 17073006 | USES OF PARASITE MACROPHAGE MIGRATION INHIBITORY FACTORS | October 2020 | November 2022 | Abandon | 25 | 1 | 0 | No | No |
| 17071425 | HUMAN-DERIVED BACTERIA THAT INDUCE PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS | October 2020 | September 2022 | Allow | 23 | 1 | 1 | Yes | No |
| 17045315 | Therapeutic Microvesicles of Probiotic Bacteria | October 2020 | August 2023 | Allow | 34 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HINES, JANA A.
With a 38.9% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 17.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HINES, JANA A works in Art Unit 1645 and has examined 845 patent applications in our dataset. With an allowance rate of 47.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.
Examiner HINES, JANA A's allowance rate of 47.5% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HINES, JANA A receive 2.42 office actions before reaching final disposition. This places the examiner in the 70% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by HINES, JANA A is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +43.6% benefit to allowance rate for applications examined by HINES, JANA A. This interview benefit is in the 90% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 17.4% of applications are subsequently allowed. This success rate is in the 15% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 25.4% of cases where such amendments are filed. This entry rate is in the 35% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 69% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 74.6% of appeals filed. This is in the 63% percentile among all examiners. Of these withdrawals, 64.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 76.4% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 3.1% of allowed cases (in the 80% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.5% of allowed cases (in the 71% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.